Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07936578
PHASE2

Clinical Study of Ivonescimab Combined With Concurrent Chemoradiotherapy in the Treatment of Advanced Non-small Cell Lung Cancer

Sponsor: Guizhou Medical University

View on ClinicalTrials.gov

Summary

This prospective, exploratory study will evaluate the objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and toxicity of ivonescimab plus chemotherapy for 2-4 cycles after concurrent chemoradiotherapy, followed by 2 years of ivonescimab maintenance therapy, in patients with stage IV non-small cell lung cancer (NSCLC). The findings will be compared with those of previous studies and with our institutional data on patients with stage IV NSCLC who received concurrent chemoradiotherapy followed by PD-1 inhibitor plus chemotherapy for 2-4 cycles and then 2 years of PD-1 inhibitor maintenance therapy. This comparison may demonstrate that, after concurrent chemoradiotherapy for stage IV NSCLC, ivonescimab plus chemotherapy for 2-4 cycles followed by 2 years of ivonescimab maintenance therapy achieves superior efficacy compared with PD-1 inhibitor plus chemotherapy for 2-4 cycles followed by 2 years of PD-1 inhibitor maintenance therapy, with a comparable toxicity profile.

Official title: A Prospective Exploratory Phase II Clinical Study of Ivonescimab Combined With Concurrent Chemoradiotherapy in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2026-10-30

Completion Date

2029-10-30

Last Updated

2026-11-13

Healthy Volunteers

No

Interventions

DRUG

Ivonescimab plus chemotherapy followed by 2-year ivonescimab maintenance after concurrent chemoradiotherapy in stage IV non-small cell lung cancer

After concurrent chemoradiotherapy, patients received 2-4 cycles of ivonescimab combined with chemotherapy, with each 3-week period defined as one dosing cycle. On Day 1 of each treatment cycle, ivonescimab was administered first by intravenous infusion; after an interval of at least 30 minutes, pemetrexed or paclitaxel/albumin-bound paclitaxel was administered intravenously. On Day 2, carboplatin or cisplatin was administered intravenously. Patients without disease progression received ivonescimab maintenance therapy for up to 2 years or until discontinuation due to toxicity-related intolerance.

Locations (1)

the Affiliated Cancer Hospital of Guizhou Medical University

Guiyang, Guizhou, China